Print
12 January 2018
GMP News
In the first 11 months of 2017, the exports of medicinal products from Russia (excluding the shipments to EAEU) reached 19.0 billion rubles (including the customs duties). This means that, when calculated in the Russian currency, the increase over the same period of 2016 was only 0.4%. However, the mere fact of positive dynamics is quite encouraging, as the results for January-October were much gloomier (at that time, the long-term growth rate was -2.2%).
The active efforts of exporters reversed the situation in November 2017. For that month, the total exports of medicinal products from Russia reached 2.3 billion rubles, an increase was 23% in ruble terms. Although this was not a record-breaking result, it is still quite outstanding, since better dynamics have been demonstrated by exporters only in January 2017, when the shipments increased by 58%.
In physical terms, the exports in November 2017 amounted to 70.8 million packages, a 22% increase year over year. Moreover, throughout the year, the general dynamics in physical terms can be described as rather successful. Despite occasional downturns reported, for example, for February when the exports in terms of shipped packages fell by 38%, the overall results for the first 11 months of 2017 have been markedly positive (+7.3%). Since the beginning of 2017, the total exports of medicinal products from Russia reached 536.4 million packages.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.